Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1993 1
1995 1
2001 2
2003 1
2005 1
2009 1
2010 2
2011 1
2012 1
2014 1
2015 5
2016 4
2017 2
2018 4
2020 4
2021 2
2022 4
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Developmental and epileptic encephalopathy, 82"
Page 1
Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.
McTague A, Martland T, Appleton R. McTague A, et al. Cochrane Database Syst Rev. 2018 Jan 10;1(1):CD001905. doi: 10.1002/14651858.CD001905.pub3. Cochrane Database Syst Rev. 2018. PMID: 29320603 Free PMC article. Review.
SEARCH METHODS: For the latest update we searched the Cochrane Epilepsy Group's Specialised Register (23 May 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 23 May 2017), MEDLINE (Ovid, 1946 to 23 May 2 …
SEARCH METHODS: For the latest update we searched the Cochrane Epilepsy Group's Specialised Register (23 May 2017), the Cochrane Cent …
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. Lux AL, et al. Lancet Neurol. 2005 Nov;4(11):712-7. doi: 10.1016/S1474-4422(05)70199-X. Lancet Neurol. 2005. PMID: 16239177 Clinical Trial.
We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes. METHODS: Infants enrolled in the United Kingdom Infantile Spasms Study (UKISS) were randomly assigned hormone treatment (n=55) or vigabatrin (n …
We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes. METHODS: I …
Early rescue of interneuron disease trajectory in developmental epilepsies.
Siehr MS, Noebels JL. Siehr MS, et al. Curr Opin Neurobiol. 2016 Feb;36:82-8. doi: 10.1016/j.conb.2015.10.007. Epub 2015 Oct 27. Curr Opin Neurobiol. 2016. PMID: 26517286 Free PMC article. Review.
The discovery of over 150 monogenic epilepsies and advances in early genetic diagnoses have launched a search for molecular strategies and developmental timetables to reverse or even prevent the course of these debilitating brain disorders. ...Several genes, even th …
The discovery of over 150 monogenic epilepsies and advances in early genetic diagnoses have launched a search for molecular strategies and …
Myoclonus in Angelman syndrome.
Pollack SF, Grocott OR, Parkin KA, Larson AM, Thibert RL. Pollack SF, et al. Epilepsy Behav. 2018 May;82:170-174. doi: 10.1016/j.yebeh.2018.02.006. Epub 2018 Mar 17. Epilepsy Behav. 2018. PMID: 29555100
Angelman syndrome (AS) is a neurogenetic imprinting disorder caused by loss of the maternally inherited Ube3a gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Myoclonic seizures are often the first sei …
Angelman syndrome (AS) is a neurogenetic imprinting disorder caused by loss of the maternally inherited Ube3a gene and is characterized by g …
Efficacy and tolerability of add-on stiripentol in real-world clinical practice: An observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies.
Gil-Nagel A, Aledo-Serrano A, Beltrán-Corbellini Á, Martínez-Vicente L, Jimenez-Huete A, Toledano-Delgado R, Gacía-Morales I, Valls-Carbó A. Gil-Nagel A, et al. Epilepsia Open. 2024 Feb;9(1):164-175. doi: 10.1002/epi4.12847. Epub 2023 Nov 8. Epilepsia Open. 2024. PMID: 37867433 Free PMC article.
OBJECTIVE: To assess efficacy and tolerability of stiripentol (STP) as adjunctive treatment in Dravet syndrome and non-Dravet refractory developmental and epileptic encephalopathies (DREEs). METHODS: Retrospective observational study of all children and adult …
OBJECTIVE: To assess efficacy and tolerability of stiripentol (STP) as adjunctive treatment in Dravet syndrome and non-Dravet refractory …
Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L, Li W, Wang C. Zhang L, et al. Acta Neurol Scand. 2021 Apr;143(4):339-348. doi: 10.1111/ane.13387. Epub 2020 Dec 17. Acta Neurol Scand. 2021. PMID: 33336426
BACKGROUND: Dravet syndrome (DS) is a severe, drug-resistant, developmental epileptic encephalopathy. Despite multiple anti-epileptic drug regimens, the syndrome remains poorly controlled and nearly half of patients still experience at least four tonic …
BACKGROUND: Dravet syndrome (DS) is a severe, drug-resistant, developmental epileptic encephalopathy. Despite multiple …
Development and validation of a diagnostic aid for convulsive epilepsy in sub-Saharan Africa: a retrospective case-control study.
Jones GD, Kariuki SM, Ngugi AK, Mwesige AK, Masanja H, Owusu-Agyei S, Wagner R, Cross JH, Sander JW, Newton CR, Sen A; EPInA Study Group. Jones GD, et al. Lancet Digit Health. 2023 Apr;5(4):e185-e193. doi: 10.1016/S2589-7500(22)00255-2. Lancet Digit Health. 2023. PMID: 36963908 Free article.
FINDINGS: We analysed epilepsy-specific data from 4097 people, of whom 1985 (48.5%) had convulsive epilepsy, and 2112 were controls. ...INTERPRETATION: On the basis of these findings, we developed the Epilepsy Diagnostic Companion as a predictive model and ap …
FINDINGS: We analysed epilepsy-specific data from 4097 people, of whom 1985 (48.5%) had convulsive epilepsy, and 2112 were con …
Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.
Terada K, Kubota Y, Dimova S, Elmoufti S, Floricel F, Chellun D, O'Brien TJ. Terada K, et al. Seizure. 2023 Nov;112:62-67. doi: 10.1016/j.seizure.2023.09.011. Epub 2023 Sep 13. Seizure. 2023. PMID: 37769545 Free article. Clinical Trial.
METHODS: Exploratory post hoc analysis of patients with temporal focus of localization (indicated as the only localization focus) in a double-blind, noninferiority, phase 3 trial (SP0993; NCT01243177) in patients aged 16 years with newly diagnosed epilepsy random …
METHODS: Exploratory post hoc analysis of patients with temporal focus of localization (indicated as the only localization focus) in a doubl …
Bilateral frontoparietal polymicrogyria.
Jain P, Sharma S, Bahi-Buisson N, Beldjord C, Aneja S. Jain P, et al. Indian J Pediatr. 2015 Apr;82(4):390-1. doi: 10.1007/s12098-014-1614-1. Epub 2014 Nov 23. Indian J Pediatr. 2015. PMID: 25416088 No abstract available.
Minimally invasive procedures for hypothalamic hamartoma-related epilepsy: a systematic review and meta-analysis.
Iranmehr A, Dabbagh Ohadi MA, Chavoshi M, Jahanbakhshi A, Slavin KV. Iranmehr A, et al. Neurosurg Focus. 2022 Oct;53(4):E8. doi: 10.3171/2022.7.FOCUS22296. Neurosurg Focus. 2022. PMID: 36183177
OBJECTIVE: Hypothalamic hamartoma (HH) is a rare, nonmalignant, heterotopic developmental malformation that consists of a mixture of normal neurons and glial cells. ...Generally, the mean incidences of overall seizure freedom after minimally invasive procedures were 77% (9 …
OBJECTIVE: Hypothalamic hamartoma (HH) is a rare, nonmalignant, heterotopic developmental malformation that consists of a mixture of …
40 results